These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28413961)

  • 21. Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain-Gut Axis.
    Farr S; Baker C; Naples M; Taher J; Iqbal J; Hussain M; Adeli K
    Arterioscler Thromb Vasc Biol; 2015 May; 35(5):1092-100. PubMed ID: 25675997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Incretin hormones in the treatment of type 2 diabetes. Part I: influence of insulinotropic gut-derived hormones (incretins) on glucose metabolism].
    Matuszek B; Lenart-Lipińska M; Nowakowski A
    Endokrynol Pol; 2007; 58(6):522-8. PubMed ID: 18205109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in micro- and nanotechnologies for the GLP-1-based therapy and imaging of pancreatic beta-cells.
    Moonschi FH; Hughes CB; Mussman GM; Fowlkes JL; Richards CI; Popescu I
    Acta Diabetol; 2018 May; 55(5):405-418. PubMed ID: 29264724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of incretin effects on plasma lipids and implications for the cardiovascular system.
    Xiao C; Dash S; Lewis GF
    Cardiovasc Hematol Agents Med Chem; 2012 Dec; 10(4):289-94. PubMed ID: 22827289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular effects of incretins in diabetes.
    Advani A; Bugyei-Twum A; Connelly KA
    Can J Diabetes; 2013 Oct; 37(5):309-14. PubMed ID: 24500557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incretin-based therapies and cardiovascular risk.
    Mannucci E; Dicembrini I
    Curr Med Res Opin; 2012 May; 28(5):715-21. PubMed ID: 22439700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The potential for renoprotection with incretin-based drugs.
    Tanaka T; Higashijima Y; Wada T; Nangaku M
    Kidney Int; 2014 Oct; 86(4):701-11. PubMed ID: 25007170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
    Gallwitz B
    Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Modulation of the incretin effect in the treatment of diabetes].
    Vidal J
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():8-11. PubMed ID: 25437459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Incretin and incretin-based therapies].
    Harada N; Inagaki N
    Nihon Rinsho; 2010 May; 68(5):931-42. PubMed ID: 20446595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is there a place for incretin therapies in obesity and prediabetes?
    Holst JJ; Deacon CF
    Trends Endocrinol Metab; 2013 Mar; 24(3):145-52. PubMed ID: 23415157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
    Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors.
    Rizzo M; Rizvi AA; Spinas GA; Rini GB; Berneis K
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1495-503. PubMed ID: 19758106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT.
    Alssema M; Rijkelijkhuizen JM; Holst JJ; Teerlink T; Scheffer PG; Eekhoff EM; Gastaldelli A; Mari A; Hart LM; Nijpels G; Dekker JM
    Eur J Endocrinol; 2013 Oct; 169(4):421-30. PubMed ID: 23864340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide.
    Grossman S
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):25S-32S. PubMed ID: 19947814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism.
    Taskinen MR; Matikainen N; Björnson E; Söderlund S; Ainola M; Hakkarainen A; Lundbom N; Sihlbom C; Thorsell A; Andersson L; Adiels M; Hartmann B; Deacon CF; Holst JJ; Packard CJ; Borén J
    Eur J Endocrinol; 2022 May; 187(1):75-84. PubMed ID: 35521766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.